Dulaglutide vs Insulin in Thalassaemia Diabetes Trial | dulaglutide thalassaemia diabetes trial

Dulaglutide vs Insulin in Adolescents With Thalassaemia-Related Diabetes

8 Min Read

Comments Off

CED Clinical Relevance #82 Clinical Evidence Update A peer-reviewed randomized controlled trial directly compared weekly dulaglutide with basal-bolus insulin for 24 weeks in 80 adolescents with transfusion-dependent beta-thalassaemia and diabetes uncontrolled on metformin.

Clinical Insight | CED Clinic

Adly and colleagues randomized 80 adolescents with transfusion-dependent beta-thalassaemia and diabetes uncontrolled on metformin to weekly dulaglutide or basal-bolus insulin. Dulaglutide improved the primary glucose-variability measure and several secondary metabolic outcomes over 24 weeks. No serious adverse event was reported in the abstract, but that is not equivalent to a complete long-term safety assessment. The study is promising, yet its small single-center population, open-label treatment, short follow-up, rare-disease setting, and incomplete abstract-level adverse-event detail require caution. It supports larger multicenter trials and specialist discussion, not independent insulin withdrawal or broad pediatric prescribing conclusions.

GLP-1DulaglutideAdolescent DiabetesThalassaemiaRandomized Trial

Audience	Families affected by transfusion-dependent thalassaemia, pediatric endocrinologists, hematologists, diabetes clinicians, and readers following GLP-1 evidence
Primary Topic	dulaglutide versus insulin in adolescents with thalassaemia-related diabetes
Source	Read the full source

Dulaglutide vs Insulin in Adolescents With Thalassaemia-Related Diabetes

In an open-label randomized trial of 80 adolescents with transfusion-dependent beta-thalassaemia and diabetes, weekly dulaglutide improved glucose variability and several metabolic measures more than basal-bolus insulin over 24 weeks. The single-center, short-duration study was exploratory and does not establish long-term safety, cardiovascular benefit, or superiority for adolescents outside this rare clinical population.

What This Study Teaches Us

Dulaglutide reduced the continuous-glucose-monitoring coefficient of variation from 39.45% to 35.05%, while the insulin group’s value increased from 39.85% to 43.26%. The standardized between-group effect size was 1.69, with a 95% confidence interval from 1.16 to 2.22. Time in range, HbA1c, fasting glucose, fructosamine, C-peptide, total cholesterol, and ferritin also favored dulaglutide in the authors’ analyses.

Why This Matters

Diabetes in transfusion-dependent thalassaemia can reflect iron-related pancreatic injury and presents a specialized management problem. This trial is clinically meaningful because it tested a GLP-1 receptor agonist against active insulin treatment in adolescents, but its findings apply to a narrow population and need independent, longer-term confirmation.

Study Snapshot

Study Type	Open-label, parallel-group randomized controlled trial with masked outcome assessment
Population	80 adolescents aged 10 to 18 years with transfusion-dependent beta-thalassaemia and diabetes uncontrolled on metformin
Setting	Ain Shams University Paediatrics Hospital, Cairo, Egypt
Intervention	Dulaglutide 0.75 mg by subcutaneous injection once weekly
Comparator	Conventional basal-bolus insulin therapy
Duration	24 weeks
Primary Outcome	Change in continuous-glucose-monitoring coefficient of variation, a measure of glycaemic variability
Primary Result	Coefficient of variation fell from 39.45% to 35.05% with dulaglutide and rose from 39.85% to 43.26% with insulin; standardized between-group effect size 1.69, 95% CI 1.16 to 2.22
Other Outcomes	Time in range, time above range, fasting glucose, HbA1c, fructosamine, fasting C-peptide, total cholesterol, and ferritin
Serious Adverse Events	No serious adverse event was reported in the abstract
Trial Registration	ClinicalTrials.gov NCT07370922
Journal	Diabetologia
Published	August 19, 2026
PMID / DOI	42618811 / 10.1007/s00125-026-06835-x
Major Limitation	Small, single-center, open-label, 24-week trial in a rare pediatric population

Clinical Bottom Line

Weekly dulaglutide produced better short-term glucose-variability and metabolic results than basal-bolus insulin in this 80-participant trial. The finding supports further study in thalassaemia-related diabetes, not a broad change in pediatric diabetes treatment or independent medication changes.

The Primary Outcome Favored Dulaglutide

The prespecified primary endpoint was glucose variability measured by the continuous-glucose-monitoring coefficient of variation.

The direction and magnitude of the between-group result favored dulaglutide, but one modest-sized trial cannot establish durability or effectiveness across different centers.

Several Metabolic Measures Also Improved

The authors reported favorable changes in time in range, fasting glucose, HbA1c, fructosamine, fasting C-peptide, total cholesterol, and ferritin.

These secondary findings are clinically interesting, but multiplicity, short follow-up, and the exploratory framing limit certainty.

Safety Evidence Is Still Limited

No serious adverse event was reported during the 24-week study.

That does not prove an absence of hypoglycaemia, gastrointestinal effects, uncommon harms, or longer-term safety concerns. The abstract does not provide a complete event table.

This Is a Highly Specific Population

Participants had transfusion-dependent beta-thalassaemia and diabetes uncontrolled on metformin, not typical adolescent type 2 diabetes.

Iron overload, pancreatic reserve, transfusion care, and chelation treatment may affect both risk and response, so generalization should be restrained.

Active Comparison Adds Value and Complexity

Comparing dulaglutide with basal-bolus insulin is more clinically informative than a placebo-only design.

The open-label treatment assignment, different administration patterns, and single-center setting can influence adherence, co-interventions, and behavior even though outcome assessors were masked.

How Strong Is This Evidence?

Random assignment, an active comparator, continuous glucose monitoring, a prespecified variability endpoint, and masked outcome assessment strengthen the short-term comparison.

Where This Paper Deserves Skepticism

The trial included only 80 participants at one center, treatment was open-label, follow-up lasted 24 weeks, the population was unusually specific, and the abstract provides incomplete adverse-event detail.

What This Paper Does Not Show

The trial does not establish long-term glycaemic durability, prevention of cardiovascular or microvascular complications, reduced mortality, superiority in ordinary type 1 or type 2 diabetes, safety in other pediatric populations, or that insulin can be stopped without specialist supervision.

How This Fits With the Broader Clinical Conversation

Thalassaemia-related diabetes is shaped by iron overload, pancreatic injury, transfusion exposure, and the broader endocrine complications of chronic disease.

For patients and families, the practical question is not whether GLP-1 therapy is universally better than insulin. It is whether the treatment fits the individual diagnosis, pancreatic reserve, glucose pattern, nutritional status, adverse-effect risk, and hematology plan.

Dr. Caplan’s Take

I read this as a promising randomized signal in a rare and clinically difficult population. The glucose-variability result is meaningful, but 24 weeks is a beginning rather than a treatment verdict.

No adolescent should change insulin or begin dulaglutide because of one paper. Any application would require coordinated pediatric endocrinology and hematology care, with close glucose and nutrition monitoring.

What a Careful Reader Should Take Away

A careful reader should conclude that dulaglutide outperformed basal-bolus insulin on short-term glucose variability and several secondary measures in this specific trial, while recognizing that larger multicenter studies are needed before practice changes.

Evidence Interpretation Guide

How to Read an Active-Comparator Trial in a Rare Pediatric Population

The design is stronger than an uncontrolled report.

The population and follow-up still sharply limit generalization.

Four distinctions that matter

Variability versus average glucose
The primary endpoint was glucose variability, while HbA1c and other metabolic measures were secondary.

Dulaglutide versus insulin
An active comparison is clinically useful, but it does not mean insulin is unnecessary for every participant or population.

Masked assessment versus open treatment
Outcome assessors were masked, while patients and clinicians knew the assigned treatment.

Short-term signal versus practice standard
Twenty-four weeks can identify a promising effect but cannot establish long-term safety or complication prevention.

The Research Question

Can weekly dulaglutide improve glycaemic variability and metabolic measures compared with basal-bolus insulin in adolescents with thalassaemia-related diabetes?

The Patient Question

Does this result mean dulaglutide should replace my insulin?

The Bottom Line

The trial supports further study and specialist discussion, not independent treatment changes.

CED Perspective Lens

The Same Study Can Mean Different Things Depending on the Question Being Asked

Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.

Lens Overview

Eight perspectives separate a promising rare-disease randomized signal from the unanswered questions about safety, durability, and generalizability.